Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Status:
Completed
Trial end date:
2017-05-19
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of veliparib in treating patients
with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.